{"organizations": [], "uuid": "1cf10542cfc23282343f0bf122fc9db0a166475d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-avid-bioservices-selected-by-acume/brief-avid-bioservices-selected-by-acumen-pharmaceuticals-to-lead-process-development-and-clinical-manufacture-of-novel-alzheimers-disease-candidate-idUSFWN1QJ0TU", "country": "US", "domain_rank": 408, "title": "Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.211, "site_type": "news", "published": "2018-03-01T21:08:00.000+02:00", "replies_count": 0, "uuid": "1cf10542cfc23282343f0bf122fc9db0a166475d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-avid-bioservices-selected-by-acume/brief-avid-bioservices-selected-by-acumen-pharmaceuticals-to-lead-process-development-and-clinical-manufacture-of-novel-alzheimers-disease-candidate-idUSFWN1QJ0TU", "ord_in_thread": 0, "title": "Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "avid bioservices inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Avid Bioservices Inc:\n* AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMERâ€™S DISEASE CANDIDATE\n* AVID BIOSERVICES - ACUMEN PHARMA SELECTED CO TO PROVIDE PROCESS DEVELOPMENT, CLINICAL MANUFACTURING SERVICES IN SUPPORT OF ACU193 Source text for Eikon:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T21:08:00.000+02:00", "crawled": "2018-03-02T19:41:48.027+02:00", "highlightTitle": ""}